Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 1
2009 1
2010 1
2013 5
2014 4
2015 8
2016 11
2017 12
2018 13
2019 24
2020 32
2021 50
2022 57
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

203 results
Results by year
Filters applied: . Clear all
Page 1
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Bardia A, et al. Among authors: tolaney sm. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. N Engl J Med. 2021. PMID: 33882206 Clinical Trial.
Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE, Tolaney SM. Keenan TE, et al. Among authors: tolaney sm. J Natl Compr Canc Netw. 2020 Apr;18(4):479-489. doi: 10.6004/jnccn.2020.7554. J Natl Compr Canc Netw. 2020. PMID: 32259782 Review.
HER2-Low Breast Cancer: Pathological and Clinical Landscape.
Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F, Penault-Llorca F, Viale G, Andrè F, Curigliano G. Tarantino P, et al. Among authors: tolaney sm. J Clin Oncol. 2020 Jun 10;38(17):1951-1962. doi: 10.1200/JCO.19.02488. Epub 2020 Apr 24. J Clin Oncol. 2020. PMID: 32330069 Review. No abstract available.
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P; monarchE Committee Members and Investigators. Johnston SRD, et al. Among authors: tolaney sm. J Clin Oncol. 2020 Dec 1;38(34):3987-3998. doi: 10.1200/JCO.20.02514. Epub 2020 Sep 20. J Clin Oncol. 2020. PMID: 32954927 Free PMC article. Clinical Trial.
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, Huang CS, Jaliffe GG, Tryakin A, Goetz MP, Rugo HS, Senkus E, Testa L, Andersson M, Tamura K, Del Mastro L, Steger GG, Kreipe H, Hegg R, Sohn J, Guarneri V, Cortés J, Hamilton E, André V, Wei R, Barriga S, Sherwood S, Forrester T, Munoz M, Shahir A, San Antonio B, Nabinger SC, Toi M, Johnston SRD, O'Shaughnessy J; monarchE Committee Members. Harbeck N, et al. Among authors: tolaney sm. Ann Oncol. 2021 Dec;32(12):1571-1581. doi: 10.1016/j.annonc.2021.09.015. Epub 2021 Oct 14. Ann Oncol. 2021. PMID: 34656740 Free article. Clinical Trial.
Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies.
Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, Cortes J, Soria JC, Curigliano G. Tarantino P, et al. Among authors: tolaney sm. CA Cancer J Clin. 2022 Mar;72(2):165-182. doi: 10.3322/caac.21705. Epub 2021 Nov 12. CA Cancer J Clin. 2022. PMID: 34767258 Free article. Review.
Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche.
Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho JW, Zhao X, Estivill G, Adam I, Sanchez X, McCarthy S, Schaller J, Khan Z, Ruzo A, Pastorello R, Richardson ET, Dillon D, Montero-Llopis P, Barroso-Sousa R, Forman J, Shukla SA, Tolaney SM, Mittendorf EA, von Andrian UH, Wucherpfennig KW, Hemberg M, Agudo J. Baldominos P, et al. Among authors: tolaney sm. Cell. 2022 May 12;185(10):1694-1708.e19. doi: 10.1016/j.cell.2022.03.033. Epub 2022 Apr 20. Cell. 2022. PMID: 35447074
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gennari A, et al. Among authors: tolaney sm. Ann Oncol. 2021 Dec;32(12):1475-1495. doi: 10.1016/j.annonc.2021.09.019. Epub 2021 Oct 19. Ann Oncol. 2021. PMID: 34678411 Free article. No abstract available.
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. Bardia A, et al. Among authors: tolaney sm. N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213. N Engl J Med. 2019. PMID: 30786188 Clinical Trial.
203 results